Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy

NCT05794139 is registered in ClinicalTrials.gov with NMD Pharma A/S as lead sponsor.

NCT NCT05794139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05794139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
Lead sponsor
NMD Pharma A/S
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2023
Completion date
May 18, 2026
Enrollment
52 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy